CO6300941A2 - Compuestos de quinuclidina como ligandos del receptor nicotinico de acetilcolina alfa 7 - Google Patents

Compuestos de quinuclidina como ligandos del receptor nicotinico de acetilcolina alfa 7

Info

Publication number
CO6300941A2
CO6300941A2 CO10131169A CO10131169A CO6300941A2 CO 6300941 A2 CO6300941 A2 CO 6300941A2 CO 10131169 A CO10131169 A CO 10131169A CO 10131169 A CO10131169 A CO 10131169A CO 6300941 A2 CO6300941 A2 CO 6300941A2
Authority
CO
Colombia
Prior art keywords
ligands
nicotinic receptor
acetilcoline
compounds
quinuclidine compounds
Prior art date
Application number
CO10131169A
Other languages
English (en)
Inventor
Ii James Cook
Ivar Mcdonald
John E Macor
Christopher Suzi
Chrisyiana Iwagwu
Nenghui Wang
Richard Olson
Dalton King
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of CO6300941A2 publication Critical patent/CO6300941A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/20—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Abstract

La revelación proporciona compuestos de fórmula I, incluyendo sus sales, así como composiciones y procedimientos de uso de los compuestos. Los compuestos son ligandos para el receptor nicotínico a7 y pueden ser útiles para el tratamiento de diversos trastornos del sistema nervioso central, en especial trastornos afectivos y neurodegenerativos.
CO10131169A 2008-04-23 2010-10-22 Compuestos de quinuclidina como ligandos del receptor nicotinico de acetilcolina alfa 7 CO6300941A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4721108P 2008-04-23 2008-04-23
US12/423,299 US7863291B2 (en) 2008-04-23 2009-04-14 Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands

Publications (1)

Publication Number Publication Date
CO6300941A2 true CO6300941A2 (es) 2011-07-21

Family

ID=41215599

Family Applications (1)

Application Number Title Priority Date Filing Date
CO10131169A CO6300941A2 (es) 2008-04-23 2010-10-22 Compuestos de quinuclidina como ligandos del receptor nicotinico de acetilcolina alfa 7

Country Status (27)

Country Link
US (1) US7863291B2 (es)
EP (1) EP2271650B1 (es)
JP (1) JP5389905B2 (es)
KR (1) KR20110015565A (es)
CN (1) CN102066384B (es)
AR (1) AR071215A1 (es)
AU (1) AU2009239575B2 (es)
BR (1) BRPI0911542A2 (es)
CA (1) CA2722325A1 (es)
CL (1) CL2009000975A1 (es)
CO (1) CO6300941A2 (es)
CY (1) CY1117045T1 (es)
DK (1) DK2271650T3 (es)
EA (1) EA017628B1 (es)
ES (1) ES2553753T3 (es)
HR (1) HRP20151111T1 (es)
HU (1) HUE028302T2 (es)
IL (1) IL208673A (es)
MX (1) MX2010011374A (es)
NZ (1) NZ588649A (es)
PE (1) PE20091977A1 (es)
PL (1) PL2271650T3 (es)
PT (1) PT2271650E (es)
SI (1) SI2271650T1 (es)
TW (1) TWI431007B (es)
WO (1) WO2009131926A1 (es)
ZA (1) ZA201007527B (es)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0911410A2 (pt) 2008-04-23 2015-10-06 Gilead Sciences Inc análogos de carba-nucleosídeo para tratamento antiviral
US8309577B2 (en) * 2008-04-23 2012-11-13 Bristol-Myers Squibb Company Quinuclidine compounds as α-7 nicotinic acetylcholine receptor ligands
BRPI0916576A2 (pt) * 2008-08-04 2017-06-27 Chdi Inc pelo menos uma entidade química, composição farmacêutica, e, método para tratar uma condição ou distúrbio.
TWI453207B (zh) * 2008-09-08 2014-09-21 Signal Pharm Llc 胺基三唑并吡啶，其組合物及使用其之治療方法
SI2480559T1 (sl) 2009-09-21 2013-10-30 Gilead Sciences, Inc. Postopki in intermediati za pripravo 1'-ciano-karbanukleozidnih analogov
US8278320B2 (en) * 2009-10-28 2012-10-02 Bristol-Myers Squibb Company Azabicyclo[2.2.1]heptane compounds as alpha-7 nicotinic acetylcholine receptor ligands
US8507516B2 (en) 2009-10-28 2013-08-13 Bristol-Myers Squibb Company Azabicyclic compounds as alpha-7 nicotinic acetylcholine receptor ligands
NZ600240A (en) * 2009-10-29 2014-04-30 Bristol Myers Squibb Co Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands
KR101764607B1 (ko) * 2010-01-14 2017-08-03 사노피 ２,５-치환된 옥사졸로피리미딘 유도체
US8481555B2 (en) * 2010-04-30 2013-07-09 Bristol-Myers Squibb Company Aza-bicyclic amine N-oxide compounds as alpha-7 nicotinic acetylcholine receptor ligand pro-drugs
KR101789129B1 (ko) 2010-06-30 2017-11-20 후지필름 가부시키가이샤 신규 니코틴아미드 유도체 또는 그 염
KR20200052384A (ko) 2010-07-19 2020-05-14 길리애드 사이언시즈, 인코포레이티드 부분입체 이성질성으로 순수한 포스포라미데이트 전구약물의 제조 방법
PT2595980E (pt) 2010-07-22 2014-11-27 Gilead Sciences Inc Métodos e compostos para tratar infeções pelo vírus da família paramyxoviridae
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
AR088218A1 (es) 2011-07-19 2014-05-21 Infinity Pharmaceuticals Inc Compuestos heterociclicos utiles como inhibidores de pi3k
MX364378B (es) 2011-08-30 2019-01-21 Chdi Foundation Inc Inhibidores de la quinurenina-3-monooxigenasa, sus composiciones farmaceuticas y metodos para uso.
WO2013056070A2 (en) 2011-10-14 2013-04-18 Ambit Biosciences Corporation Heterocyclic compounds and methods of use thereof
AR090037A1 (es) 2011-11-15 2014-10-15 Xention Ltd Derivados de tieno y/o furo-pirimidinas y piridinas inhibidores de los canales de potasio
WO2013177024A1 (en) 2012-05-24 2013-11-28 Bristol-Myers Squibb Company QUINUCLIDINE, 1-AZABICYCLO[2.2.1]HEPTANE, 1-AZABICYCLO [3.2.1]OCTANE, and 1-AZABICYCLO[3.2.2]NONANE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS
PT3176170T (pt) 2012-06-13 2019-02-05 Incyte Holdings Corp Compostos tricíclicos substituídos como inibidores de fgfr
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
CN105143222B (zh) * 2013-03-14 2018-02-02 默克专利有限公司 糖苷酶抑制剂
PE20152033A1 (es) 2013-04-19 2016-01-21 Incyte Holdings Corp Heterociclos bicicliclos como inhibidores de fgfr
WO2015116904A1 (en) 2014-02-03 2015-08-06 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ror-gamma
JP5714745B2 (ja) * 2014-04-28 2015-05-07 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ α７ニコチン性アセチルコリン受容体リガンドとしてのキヌクリジン化合物
MX2017000779A (es) 2014-07-17 2017-07-27 Chdi Foundation Inc Metodos y composiciones para el tratamiento de trastornos relacionados con el vih.
JP6563017B2 (ja) 2014-08-28 2019-08-21 エースニューロン・ソシエテ・アノニム グリコシダーゼ阻害剤
WO2016061160A1 (en) 2014-10-14 2016-04-21 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ror-gamma
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
TWI698444B (zh) 2014-10-29 2020-07-11 美商基利科學股份有限公司 製備核糖苷的方法
WO2016073407A1 (en) * 2014-11-04 2016-05-12 Bristol-Myers Squibb Company Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands
US9845308B2 (en) 2014-11-05 2017-12-19 Vitae Pharmaceuticals, Inc. Isoindoline inhibitors of ROR-gamma
US9663515B2 (en) 2014-11-05 2017-05-30 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
EP3617205B1 (en) 2015-02-20 2021-08-04 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
ES2856931T3 (es) 2015-08-05 2021-09-28 Vitae Pharmaceuticals Llc Moduladores de ROR-gamma
CA2998189C (en) 2015-09-16 2021-08-03 Gilead Sciences, Inc. Methods for treating arenaviridae and coronaviridae virus infections
RU2018121946A (ru) 2015-11-20 2019-12-23 Вайтаи Фармасьютиклз, Ллк Модуляторы ror-гамма
TW202220968A (zh) 2016-01-29 2022-06-01 美商維它藥物有限責任公司 ＲＯＲ－γ調節劑
WO2017144633A1 (en) 2016-02-25 2017-08-31 Asceneuron S. A. Glycosidase inhibitors
CN108884078A (zh) 2016-02-25 2018-11-23 阿森纽荣股份公司 糖苷酶抑制剂
EA201891438A1 (ru) 2016-02-25 2019-01-31 Асенейрон С. А. Кислотно-аддитивные соли производных пиперазина
US11261183B2 (en) 2016-02-25 2022-03-01 Asceneuron Sa Sulfoximine glycosidase inhibitors
US9481674B1 (en) 2016-06-10 2016-11-01 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
CN110869028B (zh) 2017-03-14 2023-01-20 吉利德科学公司 治疗猫冠状病毒感染的方法
MX2019010302A (es) 2017-03-30 2019-11-21 Hoffmann La Roche Isoquinolinas como inhibidores de hpk1.
CN115403626A (zh) 2017-05-01 2022-11-29 吉利德科学公司 新结晶形式
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
US10675296B2 (en) 2017-07-11 2020-06-09 Gilead Sciences, Inc. Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections
MA49685A (fr) 2017-07-24 2021-04-14 Vitae Pharmaceuticals Llc INHIBITEURS DE ROR gamma
WO2019018975A1 (en) 2017-07-24 2019-01-31 Vitae Pharmaceuticals, Inc. INHIBITORS OF ROR GAMMA
US11213525B2 (en) 2017-08-24 2022-01-04 Asceneuron Sa Linear glycosidase inhibitors
CN107868039A (zh) * 2017-11-27 2018-04-03 中国药科大学 一种贝曲沙班中间体n－（5－氯－2－吡啶基）－2－［（4－氰基苯甲酰基）氨基］－5－甲氧基苯甲酰胺的制备方法
CN112867716A (zh) 2018-05-04 2021-05-28 因赛特公司 Fgfr抑制剂的固体形式和其制备方法
CA3099116A1 (en) 2018-05-04 2019-11-07 Incyte Corporation Salts of an fgfr inhibitor
WO2020039029A1 (en) 2018-08-22 2020-02-27 Asceneuron S. A. Spiro compounds as glycosidase inhibitors
US11795165B2 (en) 2018-08-22 2023-10-24 Asceneuron Sa Tetrahydro-benzoazepine glycosidase inhibitors
US11612606B2 (en) 2018-10-03 2023-03-28 Genentech, Inc. 8-aminoisoquinoline compounds and uses thereof
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
KR20220056177A (ko) 2019-08-30 2022-05-04 다이니뽄 스미토모 세이야쿠 가부시키가이샤 2-아미노퀴나졸리논 유도체
JOP20220083A1 (ar) 2019-10-14 2023-01-30 Incyte Corp حلقات غير متجانسة ثنائية الحلقة كمثبطات لـ fgfr
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
CA3163875A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
CA3162010A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Derivatives of an fgfr inhibitor
WO2021154687A1 (en) 2020-01-27 2021-08-05 Gilead Sciences, Inc. Methods for treating sars cov-2 infections
CN115298181A (zh) 2020-03-12 2022-11-04 吉利德科学公司 制备1’-氰基核苷的方法
EP4132651A1 (en) 2020-04-06 2023-02-15 Gilead Sciences, Inc. Inhalation formulations of 1'-cyano substituted carbanucleoside analogs
CA3179226A1 (en) 2020-05-29 2021-12-02 Tomas Cihlar Remdesivir treatment methods
CN115996928A (zh) 2020-06-24 2023-04-21 吉利德科学公司 1’-氰基核苷类似物及其用途
PE20231983A1 (es) 2020-08-27 2023-12-12 Gilead Sciences Inc Compuestos y metodos para el tratamiento de infecciones virales
US11939331B2 (en) 2021-06-09 2024-03-26 Incyte Corporation Tricyclic heterocycles as FGFR inhibitors
WO2023167944A1 (en) 2022-03-02 2023-09-07 Gilead Sciences, Inc. Compounds and methods for treatment of viral infections

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8808433D0 (en) * 1988-04-11 1988-05-11 Merck Sharp & Dohme Therapeutic agents
US5053412A (en) 1990-04-10 1991-10-01 Israel Institute For Biological Research Spiro nitrogen-bridged heterocyclic compounds
IL97726A (en) 1990-04-10 1994-12-29 Israel Inst Biolog Res Pharmaceutical preparations containing compounds with bridged and unbridged heterocyclic groups connected via spiro-atop with oxazoline and thiazoline groups, and sharp compounds
US5534520A (en) * 1990-04-10 1996-07-09 Fisher; Abraham Spiro compounds containing five-membered rings
CN1056846C (zh) * 1994-08-24 2000-09-27 阿斯特拉公司 治疗学上有效的螺－氮杂二环化合物
MXPA04010921A (es) 2002-05-03 2005-05-27 Israel Inst Biolog Res Metodos y composiciones para el tratamietno de trastornos del sistema nervioso central y periferico y compuestos novedosos utiles para los mismos.
EP1654264A1 (en) 2003-07-08 2006-05-10 AstraZeneca AB Spiro [1-azabicyclo [2.2.2]octane-3,5'-oxazolidin-2'-one] derivatives with affinity to the alpha7 nicotinic acetylcholine receptor
JP2008524208A (ja) 2004-12-15 2008-07-10 アストラゼネカ・アクチエボラーグ ニコチン性アセチルコリン受容体リガンド
US20070004715A1 (en) 2005-06-30 2007-01-04 Yifang Huang Novel spiro-quinuclidinyl derivatives for the treatment of central nervous system disorders
ITMI20061279A1 (it) 2006-06-30 2008-01-01 Consiglio Nazionale Ricerche Agonisti nicotinici selettivi per il sottotipo recettoriale alfa7,procedimento per la loro preparazione e relative composizioni farmaceutiche
US8309577B2 (en) * 2008-04-23 2012-11-13 Bristol-Myers Squibb Company Quinuclidine compounds as α-7 nicotinic acetylcholine receptor ligands

Also Published As

Publication number Publication date
MX2010011374A (es) 2010-11-12
CN102066384A (zh) 2011-05-18
HUE028302T2 (en) 2016-12-28
JP5389905B2 (ja) 2014-01-15
IL208673A0 (en) 2010-12-30
AR071215A1 (es) 2010-06-02
US20090270405A1 (en) 2009-10-29
PT2271650E (pt) 2015-12-01
AU2009239575B2 (en) 2014-02-20
CL2009000975A1 (es) 2011-02-18
ES2553753T3 (es) 2015-12-11
DK2271650T3 (en) 2015-12-21
AU2009239575A1 (en) 2009-10-29
CY1117045T1 (el) 2017-04-05
TW200948812A (en) 2009-12-01
IL208673A (en) 2013-09-30
PL2271650T3 (pl) 2016-03-31
CA2722325A1 (en) 2009-10-29
HRP20151111T1 (hr) 2015-12-18
EP2271650A1 (en) 2011-01-12
BRPI0911542A2 (pt) 2015-10-13
JP2011518831A (ja) 2011-06-30
TWI431007B (zh) 2014-03-21
WO2009131926A1 (en) 2009-10-29
EA201001696A1 (ru) 2011-06-30
EP2271650B1 (en) 2015-09-16
CN102066384B (zh) 2014-07-30
SI2271650T1 (sl) 2015-12-31
NZ588649A (en) 2012-05-25
PE20091977A1 (es) 2010-01-15
EA017628B1 (ru) 2013-01-30
US7863291B2 (en) 2011-01-04
KR20110015565A (ko) 2011-02-16
ZA201007527B (en) 2012-03-28

Similar Documents

Publication Publication Date Title
CO6300941A2 (es) Compuestos de quinuclidina como ligandos del receptor nicotinico de acetilcolina alfa 7
BR112016025423A2 (pt) compostos e composições como agonistas de receptores do tipo toll 7
SV2010003662A (es) Derivados de azetidina y ciclobutano como inhibidores de jak ref. x-19081
ECSP12012326A (es) Derivados de aminopirimidina como moduladores de la lrrk2
ECSP13012611A (es) Derivados de pirazol-aminopirimidina como moduladores de la lrrk2
CL2012003604A1 (es) Compuestos heterociclicos derivados de piridina carboxamida sustituida; proceso de preparacion; composicion farmaceutica; combinacion farmaceutica; uso en el tratamiento de trastornos proliferativos celulares, enfermedad de parkinson, cancer, entre otros.
GT201300179A (es) Derivados heterociclicos novedosos y su uso en el tratamiento de trastornos neurologicos
CU20100159A7 (es) Compuestos
CR11145A (es) Pirazol amidas de acidos carboxilico utiles como microbicidas
CL2020000375A1 (es) Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre.
CU23824A3 (es) Compuestos tricíclicos y sus composiciones
PA8795601A1 (es) Derivados de azaciclilisoquinolinona e isoindolinona como antagonistas de histamina-3
ECSP17010481A (es) Novedosas pirimidinas 2,5-sustituidas
CL2019001669A1 (es) Pirazolo[3,4-b]piridinas e imidazo[1,5-b]piridazinas como inhibidores de pde1.
CO6470823A2 (es) Piperidinas sustituidas
NI201800043A (es) Nuevos derivados de imidazo[4,5-b]piridina como inhibidores duales de dyrk1/clk1
UY33565A (es) Compuestos de tetrahidrofuranilo disustituidos como antagonistas de bradiquinina-B1
CO2017001523A2 (es) Novedosas pirimidinas 2,5-sustituidas
CO2017003305A2 (es) Derivados de la amida del ácido 2-[piridin-3-il]-2,3-dihidro-benzo[1,4]dioxin-5-carboxílico o del 2-[piridin-3-il]-2,3-dihidro-benzo[1,4]dioxin-5-carbonitrilo como inhibidores de aldosterona sintasa
UY33722A (es) Oxazolidinonas como moduladores de mglur5
ECSP11011217A (es) Microbiocidas nuevos.
ECSP088176A (es) Derivados de azinil-3-sulfonilindazol como ligandos de5-hidroxitriptamina-6
CR9734A (es) Derivados de 3-sulfonilindazol sustituido como ligandos de 5-hidroxitriptamina-6
PE20160933A1 (es) Antagonista selectivos de nr2b
TN2012000191A1 (en) Quinuclidine compounds as alpha-7nicotinic acetylcholine receptor ligands

Legal Events

Date Code Title Description
FG Application granted